Tesamorelin
Also known as: Egrifta, TH9507
Brand names: Egrifta, Egrifta SV, Egrifta WR
Tesamorelin is an FDA-approved synthetic growth hormone releasing hormone analog specifically indicated for reducing excess abdominal fat in HIV-infected patients with lipodystrophy. A new weekly reconstitution formulation (Egrifta WR) was approved in 2025. Clinical trials demonstrated significant reductions in visceral adipose tissue. While approved only for HIV-related lipodystrophy, it has gained interest for targeting stubborn abdominal fat. Note: Brand pricing exceeds $10,000/month; the costs shown reflect compounding pharmacy and insurance-adjusted ranges.
Synthetic GHRH analog that reduces visceral adipose tissue by stimulating growth hormone production
| Parameter | Detail |
|---|---|
| Administration | Subcutaneous injection |
| Typical Dose | 2mg daily |
| Frequency | Daily |
Common Side Effects
Serious Side Effects
- Active malignancy
- Pregnancy
- Disruption of hypothalamic-pituitary axis
- Hypersensitivity to tesamorelin or mannitol
Evidence Quality
Clinical Trial Phase
Approved (post-market)
| Peptide | Monthly Cost | FDA Status |
|---|---|---|
| Tesamorelin | $200 - $1500/mo | FDA Approved |
| MK-677 | $50 - $100/mo | Phase 2 |
| CJC-1295 | $35 - $70/mo | Category 2 (pending reclassification) |
| Ipamorelin | $35 - $70/mo | Category 2 (pending reclassification) |
| GHRP-6 | $35 - $70/mo | Not submitted |
Medical Disclaimer
The information provided on this page is for educational and informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or modifying any peptide therapy or medication. PeptideVS does not endorse, recommend, or promote the use of any specific peptide for medical treatment. Clinical data cited may be from ongoing trials and is subject to change. Individual results may vary.